P3.02-006 Monitoring Genetic Alterations in Plasma During Anti-Cancer Treatment in Advanced NSCLC (Magic1-Validation Cohort: Preliminary Results)

No molecular markers are available so far to predict the efficacy of treatment and to monitor outcome in patients with EGFR-ALK-ROS1 wild-type advanced non-small cell lung cancer (wtNSCLC). Detection of genetic alterations in plasma may allow to follow biological effects of treatment without invasive procedures. Aim of this study (validation cohort) is to evaluate the detection rate and to monitor tumor-associated mutations in plasma during treatment in wtNSCLC.